Eligibility for Human Leukocyte Antigen–Based Therapeutics by Race and Ethnicity

IMPORTANCE: The development of therapeutics for patients who are positive for specific human leukocyte antigen (HLA) subtypes evokes the question of whether certain racial and ethnic groups are more or less likely to be eligible for novel products. OBJECTIVE: To determine whether racial and ethnic i...

Descripción completa

Detalles Bibliográficos
Autores principales: Olivier, Timothée, Haslam, Alyson, Tuia, Jordan, Prasad, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603498/
https://www.ncbi.nlm.nih.gov/pubmed/37883087
http://dx.doi.org/10.1001/jamanetworkopen.2023.38612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603498/
https://www.ncbi.nlm.nih.gov/pubmed/37883087
http://dx.doi.org/10.1001/jamanetworkopen.2023.38612

Ejemplares similares